A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
University Health Network, Toronto
Gustave Roussy, Cancer Campus, Grand Paris
GlaxoSmithKline
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
University of Cincinnati
iTeos Therapeutics
Gruppo Oncologico del Nord-Ovest